Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran ; Hereditary Angioedema Patient-Focused Research at AAAAI 2026
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
American Uranium Expands its Lo Herma ISR Uranium Project in Wyoming's Powder River Basin as Company Secures Strategically Located Uranium Mineral Rights and Stakes Additional Mining Claims
